文献速递肿瘤 PET/CT核素与放射性配体治疗

靶向药物与免疫治疗时代FDG PET/CT用于黑色素瘤疗效评估的优势与挑战

The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-04-07

本综述讨论黑色素瘤新兴靶向治疗与免疫治疗的作用机制及毒性,为FDG PET/CT用于疗效评估提供框架。作者提出:BRAF突变信号相关药物治疗中PET最大价值在于早期评估耐药;抗CTLA4治疗中免疫 flare 可影响早期评估但可识别潜在危及生命的自身免疫反应;抗PD1/PDL1治疗中FDG PET/CT的作用更类似于其他接受传统化疗的实体恶性肿瘤。仍需进一步研究优化扫描时机与疗效标准。

要点

  • BRAF突变信号相关药物治疗中,PET最大价值在于早期评估耐药。
  • 抗CTLA4治疗中免疫 flare 可影响早期评估,但可识别潜在危及生命的自身免疫反应。
  • 抗PD1/PDL1治疗中FDG PET/CT作用更类似其他实体瘤化疗中的使用。

核心结论

  • 作者提出BRAF突变信号相关药物治疗中PET最大价值在于早期评估耐药。
  • 作者提出抗CTLA4治疗中免疫 flare 可影响早期评估但可识别潜在危及生命的自身免疫反应。
  • 作者提出抗PD1/PDL1治疗中FDG PET/CT作用更类似其他接受传统化疗的实体恶性肿瘤。
  • 作者指出仍需进一步研究优化该病扫描时机与疗效标准。

研究设计与样本

  • 本综述讨论黑色素瘤新兴靶向治疗与免疫治疗的作用机制及毒性,为FDG PET/CT用于疗效评估提供框架。

主要发现

  • BRAF突变信号相关药物、抗CTLA4治疗与抗PD1/PDL1治疗的作用机制和应答时间特征差异显著,给疗效判读带来复杂性。
  • 抗CTLA4治疗中免疫 flare 可影响早期疗效评估。
  • 抗CTLA4治疗中免疫 flare 可识别潜在危及生命的自身免疫反应。

临床怎么用

  • 作者提出BRAF突变信号相关药物治疗中PET最大价值在于早期评估耐药。
  • 作者提出抗CTLA4治疗中免疫 flare 可影响早期评估但可识别潜在危及生命的自身免疫反应。
  • 作者提出抗PD1/PDL1治疗中FDG PET/CT作用更类似其他接受传统化疗的实体恶性肿瘤。
  • 作者指出仍需进一步研究优化该病扫描时机与疗效标准。

局限性

  • 作者指出仍需进一步研究优化该病扫描时机与疗效标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment of melanoma has been revolutionised in recent years by advances in the understanding of the genomic landscape of this disease, which has led to the development of new targeted therapeutic agents, and the ability to therapeutically manipulate the immune system through inhibition of cancer cell-T-cell interactions that prevent an adaptive immune response. While these therapeutic interventions have dramatically improved the prospects of survival for patients with advanced melanoma, they bring significant complexity to the interpretation of therapeutic response because their mechanisms and temporal profile of response vary considerably. In this review, we discuss the mode of action of these emerging therapies and their toxicities to provide a framework for the use of FDG PET/CT in therapeutic response assessment. We propose that the greatest utility of PET in assessment of response to agents that abrogate signalling related to BRAF mutation is for early assessment of resistance, while in anti-CTLA4 therapy, immunological flare can compromise early assessment of response but can identify potentially life-threatening autoimmune reactions. For anti-PD1/PDL1 therapy, the role of FDG PET/CT is more akin to its use in other solid malignancies undergoing treatment with conventional chemotherapy. However, further research is required to optimise the timing of scans and response criteria in this disease.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wong ANM, McArthur GA, Hofman MS, et al. The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. Eur J Nucl Med Mol Imaging. 2017. PMID: 28389693. doi:10.1007/s00259-017-3691-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。